Physician profile
Anthony Ocon
NPI 1932547627
$29,245.47
in general payments reported to CMS, 2019-2025
10 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $99.00 · 2021: $278 · 2022: $685 · 2023: $1,419 · 2024: $3,617 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $4,603 · Food and Beverage: $4,312 · Education: $279 · Travel and Lodging: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,750.00 |
| Consulting Fee | $4,602.75 |
| Food and Beverage | $4,312.15 |
| Education | $278.98 |
| Travel and Lodging | $139.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25,199.68 | 2022-2025 | Tavneos, Otezla, Uplizna |
| Glaxosmithkline, LLC. | $1,144.41 | 2022-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $964.97 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals Lp | $777.12 | 2021-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $587.09 | 2021-2024 | Tremfya |
| Abbvie INC. | $258.50 | 2024-2025 | |
| Ucb, INC. | $104.00 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.77 | 2024 | |
| Aurinia Pharma U.S., INC. | $97.21 | 2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $14.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ocon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.